Copyright
©The Author(s) 2024.
World J Virol. Mar 25, 2024; 13(1): 89104
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.89104
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.89104
Table 1 Patient demographics of the chronic hepatitis group
Patient demographics | Number of patients | Percentage | |
Sex | Female | 1 | 11.1 |
Male | 8 | 88.9 | |
Malignancy | ALL | 1 | 11.1 |
Colon | 2 | 22.2 | |
HCC | 5 | 55.6 | |
Pancreas | 1 | 11.1 | |
USG | Coarse liver | 5 | 55.6 |
Normal | 4 | 44.4 | |
Past history of jaundice | No | 4 | 44.4 |
Yes | 5 | 55.6 | |
Positive family history | No | 8 | 88.9 |
Yes | 1 | 11.1 | |
Past history of surgeries | No | 8 | 88.9 |
Yes | 1 | 11.1 | |
History of transfusion in the past | No | 8 | 88.9 |
Yes | 1 | 11.1 | |
History of acute hepatitis B in the past | No | 6 | 66.6 |
Yes | 3 | 33.3 |
Table 2 Baseline hepatitis B virus DNA levels of the chronic hepatitis with follow-up at 6 and 12 months after the introduction of prophylaxis (tenofovir or entecavir)
Patient | 0 months | 6th months | 12th months | |||
HBV DNA | Liver enzymes | HBV DNA | Liver enzymes | HBV DNA | Liver enzymes | |
1 | TND | Normal | TND | Normal | TND | Normal |
2 | TND | Normal | TND | Normal | TND | Normal |
3 | TND | Normal | TND | Normal | TND | Normal |
4 | TND | Normal | TND | Normal | TND | Normal |
5 | TND | Normal | TND | Normal | TND | Normal |
6 | TND | Normal | TND | Normal | TND | Normal |
7 | TND | Normal | TND | Normal | TND | Normal |
8 | HIGH | Elevated > 2X UNL | TND | Normal | TND | Normal |
9 | HIGH | Elevated > 2X UNL | TND | Normal | TND | Normal |
Table 3 Patient demographics of the occult hepatitis B infection group
Patient demographics | No. of patients | Percentage | |
Age | 52 yr | 1 | 33.3 |
75 yr | 1 | 33.3 | |
78 yr | 1 | 33.3 | |
Sex | Female | 1 | 33.3 |
Male | 2 | 66.7 | |
Malignancy | AML | 1 | 33.3 |
Colon | 1 | 33.3 | |
NSGCT | 1 | 33.3 | |
USG | Normal | 1 | 33.3 |
Coarse liver | 2 | 66.7 | |
History of Jaundice | Yes | 2 | 66.7 |
No | 1 | 33.3 | |
History of blood transfusion in the past | Yes | 1 | 33.3 |
No | 2 | 66.7 | |
History of surgery in the past | Yes | 1 | 33.3 |
No | 2 | 66.7 | |
Family history | Yes | 0 | 0.0 |
No | 3 | 100.0 |
Table 4 Baseline hepatitis B virus DNA levels of occult hepatitis B infection group and follow-up at 6 and 12 months after the introduction of prophylaxis (tenofovir or entecavir)
Patient | 0 months | 6th months | 12th months | |||
HBV DNA | Liver enzymes | HBV DNA | Liver enzymes | HBV DNA | Liver enzymes | |
1 | TND | Normal | TND | Normal | TND | Normal |
2 | TND | Normal | TND | Normal | TND | Normal |
3 | TND | Normal | TND | Normal | TND | Normal |
- Citation: Sudevan N, Manrai M, Tilak TVSVGK, Khurana H, Premdeep H. Chronic hepatitis B and occult infection in chemotherapy patients - evaluation in oncology and hemato-oncology settings: The CHOICE study. World J Virol 2024; 13(1): 89104
- URL: https://www.wjgnet.com/2220-3249/full/v13/i1/89104.htm
- DOI: https://dx.doi.org/10.5501/wjv.v13.i1.89104